Future of Healthcare Submission

oireachtas-submission-report-cover

 

FUTURE

OF

HEALTHCARE

SUBMISSION

 

 

In the last newsletter we discussed IMSTA’s formal submission to the Oireachtas Committee on the Future of Healthcare, the all-party committee set up by the Minister for Health Simon Harris T.D. when this Government came into power.

We will presently follow up on that submission with a policy proposition for the Minister and DoH the focus of which will be to realize the value of medtech to the health system and the economy. The proposition will focus on aligning expertise and methods to develop a pragmatic approach to the evaluation of medical technologies for use in the public health system in Ireland. It will propose a value-based healthcare approach to the assessment of procedures, therapies and medical technologies.

A first draft of the policy proposition should be ready in time for the IMSTA Board meeting in December and it will be presented it to our Platinum Members prior to that. We expect that it will form the basis of our presentation to the Oireachtas Committee on the Future of Healthcare.

We are currently in discussions with three consultancy firms to work with us on this proposal.

DAVY Brexit Seminar for IMSTA Members

davy_private-clients

Davy group were one of our affiliate sponsors at the recent IMSTA AWARDS and as a follow on from that they are hosting a presentation on BREXIT for IMSTA principals on November 23rd in Davy’s corporate HQ on Dawson St.

Davy presentation will cover the consequences of Brexit for Irish Business. The UK’s historic vote to leave the European Union (EU) is the start, not the end, of the exit process. The political and economic impacts of the BREXIT decision will play out over time, but Davy will attempt to lay out the initial steps towards an exit.

If you or a member of your management team would like to attend a Brexit seminar in November at Davy Groups head offices in Dawson Street please contact doreen.oreilly@imsta.ie

Mark Keating, WHITEWATER, and his dog PAGO, “Walk for their lives”

Mark Keating has just returned from an almost four month Walk For Their Lives expedition through six countries in the Balkans. He under took the walk to raise funds for two special beds that are needed in St John’s Cancer Ward in Our Lady’s Hospital for Sick Children in Crumlin, and similar requirements for a children’s cancer ward in Belgrade, Serbia.

Alone with his dog, Pajo, Mark– who is the CEO of Sandyford-based company Whitewater – went on a voyage inspired by a journey taken 100 years ago this year by his great grandfather and his grandfather-in-law.

His Irish great grandfather was with the London Irish Regiment and his grandfather-in-law was from Serbia. Their stories came together as they had to walk for their lives on the same side during the First World War, and, incredibly, survived.

In October 1915, the last survivors of the Serbian army, government, civilians, and some 30,000 boys were evacuated from their homes and country as they were chased by the German, Austrian and Bulgarian armies out of their homeland.

Some 450,000 people – comprising soldiers, refugees, families and young boys – set off to escape capture by walking over the high mountains of Montenegro and Albania to the relative safety of the tiny island of Corfu.

Mark and Pajo walked 1,990km for 103 days across 6 countries: Serbia, Bosnia, Montenegro, Albania, Greece and Macedonia, and managed to raise €12,000 for the cause, so far.

S p e a k i n g  t o  us he said: “My great-grandfather fought and survived and he gave me life and my wife’s Grandfather was the same, so this was a walk to remember the living rather than the dead, and to remember how tough the fight was to live.”

Mark’s quest drew from the “similarities of my great grandfather’s walk for life and the children today who are fighting for their lives to rid themselves of cancer, and that’s where the connection came in and how the story evolved”.

This is not Keating’s first adventure for the cause. In 2013, he undertook a solo charity cycle from Dublin to Belgrade and back to Dublin – a total of 6,080km across 12 countries, to raise €60,000 to buy critical lifesaving equipment for Temple Street Children’s University Hospital, Our Lady’s Children’s Hospital, Crumlin and The Mother and Child Hospital in Belgrade.

Mark wants encourage anybody at all to support the cause and help the children by donating to www.whitewaterfoundation.org.

PROCUREMENT: The Unexpected Driver of Value-Based Health Care

Value-based procurement of medical technology is already a reality in Europe.  Several contracting authorities are using health care quality and longer-term cost impact considerations in their procurement decisions.  This enables them to take patient outcomes into consideration as well as other qualitative criteria, along with the total lifecycle cost and longer-term costs of care, so as to ensure the best value for the patient, the medical staff, the entire hospital group and society.

The Boston Consulting Group and MedTech Europe, in partnership with non-industry procurement experts, have developed a framework to reflect this new way of thinking, as well as a practical tool to help implement value-based procurement of medical technology.   IMSTA will be trialling this tool in early 2016 with both public and private health hospital groups and will more than likely seek input from some of our members before it is launched in March 2016.  We expect to have it presented at our Annual Conference on 6th April – make sure you put that date in your diary!  This could really be a breakthrough in the procurement of medtech in Ireland.

The innovative approach echoes the 2014 EU public procurement directive which puts a strong focus on total economic value by making the Most Economic Advantageous Tender (MEAT) the default criteria, and encourages the use of “best value for money” in tendering practices.

 

One of IMSTA’s priorities in 2016 will be to ensure that value-based procurement of medical technology becomes the common practice in Ireland.

WELCOME NEW COUNCIL MEMBER – MARK CHAPMAN, Medtronic

IMSTA’s Chairman and Board of Directors are pleased to welcome Mark Chapman to the IMSTA Council.

Mark has been with Medtronic since 2001, and currently heads the Health Economics team where he is responsible for Medtronic’s strategies as related to Health Economics, economic regulator submissions and associated clinical study design as related to the quantification of cost and effectiveness. Prior to joining Medtronic, he trained as a Clinical Physiologist, and worked for 11 year within the UK NHS, Tertiary Cardiac Care, with a specialist interest in complex cardiac devices.

Mark currently sits as the Med-Tech Industry representative within NICE technology appraisal programme and is a member of the External Advisory Board, University of Leeds EPSRC Centre for innovative Manufacturing of Medical Devices. Previously has also undertaken secondment within the UK Government, Office for Life Science, Department of Business, as Med Tech Policy Advisor. Supporting the work of the UK Life Sciences Strategy.  

Mark holds; a BSc (Hons) in Applied Biological Sciences from Manchester Metropolitan University, Post Graduate Diploma –Health Economics from York University and received his MBA from Keele University, School of Public Policy.

Code of Ethics News and Christmas Hospitality/Gift Notice

MedTech Europe has agreed to phase out direct sponsorship of healthcare professionals to third-party medical conferences. After two years of work, Eucomed and EDMA codes of ethics have been updated and a single MedTech Europe Code of Ethical Business Practice has been established. On 2nd December, all Medtech Europe members voted at their Annual General Assembly to: – 

  1. Introduce new industry support models for medical education of healthcare professionals.
  2. Phase out direct sponsoring of healthcare professionals to third-party medical conferences, as of 1 January 2018.
  3. Define, secure and frame educational grants in order to prevent misuse.

IMSTA supports these new measures and our Ethics & Compliance Group will meet early in the new year to discuss how best to integrate these changes into a new revised code of Ethical Business Practice for our members. The Ethics & Compliance Group Steering will develop a programme to assist members understand and build awareness of the new changes. 

We would like to take this opportunity to bring your attention to our seasonal notice on hospitality and gifts, which this year would seem to be particularly relevant.

In an effort to promote compliance with the ethical business practices enshrined in IMSTA’s Code of Ethics, we are asking our member companies again not to engage in the traditional custom of providing hospitality and gifts to Healthcare Professionals this Christmas.

This is in line with the Medical Council guidelines on the relationships between doctors and industry and indeed the Framework for the Corporate and Financial Governance of the HSE: Codes of Standards and Behaviour.

We recommend that IMSTA member companies advise all their representatives of our position and, if necessary, issue their own letter to customers.

It may be appropriate in some instances for IMSTA members to consider making a charitable donation to an appropriate deserving cause, in lieu of the traditional Christmas gift, much the same as the Christmas Card initiative in the national newspapers.

IMSTA membership requires members to comply with the Code, which highlights the integrity of the Association and sets the standard of behaviour for the vast majority of medical supply and service companies operating in the market. 

 

.

Medical Technology showcased to Taoiseach and healthcare stakeholders

6th October 2010 Dublin

Improved patient care and savings of €200 million a year highlighted Wednesday 6th October 2010: The Taoiseach and key stakeholders in Irish healthcare were provided with a showcase of medical technology that could save the Exchequer over €70 million every year, at a special event in Dublin today.

IMSTA, the association representing medical technology supply companies in Ireland, hosted the showcase of new technology, medical devices and diagnostic equipment. Some of the products on display, including stents, remote monitoring equipment and pain management devices, have been researched and developed in Ireland.

This technology facilitates earlier diagnosis, less invasive treatment options, shorter hospital stays, reduced risk of hospital infections and faster recovery times for patients. As a result, greater use of the medical technology available can reduce the overall healthcare costs in Ireland. The industry estimates that the Exchequer could benefit from savings of over €200 million every year, while facilitating improved heath care services.

Twenty of the top medical technology companies in Ireland provided the Taoiseach, TDs, health insurers, stakeholders and healthcare specialists with an insight into the vital role medical technology plays in this country.

Mr. Justin Carty, Chief Executive, IMSTA, said it was important that the key stakeholders saw for themselves the technology being developed, produced and used in Ireland.

“Medical technology can contribute to greater healthcare savings, improved quality of life for patients and job creation in this country. The industry currently employs 30,000 people and we believe that, by giving the decision makers an opportunity to see for themselves the benefits of medical technology, we can encourage a greater role for our industry in healthcare development,” he said.

Welcoming the Government’s new Research Prioritisation Steering Group, which will be investing €598 million on academic and commercially-focused research and development spread across all Government departments and agencies, Mr Carty said that there was also a need to look at the current Government procurement processes and cooperation between the Departments of Health and Enterprise.

“Patients will have faster access to new products and jobs in the medical technology supply industry will be sustained by improving the way this technology is evaluated and procured. IMSTA members also believe that the Department of Health and Children must work closely with the Enterprise department and its agencies to maximise the benefits of international medical technology companies setting up in Ireland.”

Details of the exhibits:

(The Taoiseach’s speech will also be released to the media on the day)

Medical Technology Could Save Exchequer Over €200 million annually

October 2010 Dublin

Using the latest technology in medical devices, diagnostic equipment and healthcare ICT could save the health services and the Exchequer over €200 million every year, by improving hospital processes, surgery techniques and treatment as well as reducing hospital stays.

IMSTA, the association representing medical technology supply companies in Ireland, said that assessing the real cost-benefits rather than simply looking at costs would make a tangible difference to people’s lives, the Exchequer and provide better value for money for the taxpayers.

Announcing details of the IMSTA Medical Technology Showcase at the Alexander Hotel, Dublin, on Wednesday 6th October, Mr. Justin Carty, IMSTA Chief Executive, said that the Government and health administrators must focus on how technology that improves patient’s lives can provide real value for money.

“For example IMSTA reviewed nine medical technology products supplied by member companies. The results show that, as well as improving patient care, increased use of these products could provide savings of over €40 million every year.

The health service needs a practical technology assessment procedure as the ‘one-fits-all’ approach is not working. Medical technology is not the same as bread or milk and cannot be procured as such. The Department of Health and Children and the HSE must embrace medical technology as a critical enabler in the delivery of cost-effective, high-quality care,” he said.

Mr Carty urged the HSE and the Department to work with the industry so it can share its international experience and find ways to ensure patients get the care they are entitled to, within the constraints of the current economic climate.

“If you stop purchasing insulin pumps for those with type-1 diabetes, these patients will require increased monitoring, more in-patient care and increased demands on A&E facilities,” he explained.

IMSTA is hosting a showcase in the Alexander Hotel, Dublin on Wednesday 6th October from 11a.m. till 4pm.

With over 20 exhibitors attending, this showcase will inform stakeholders of the key role the industry plays in Irish healthcare and the contribution its research and development plays in keeping Exchequer costs down.

Key leaders in healthcare, civil servants, representatives from relevant State agencies and health insurers will be able to see the benefits of medical technology in modern Ireland.

The medical technology industry in Ireland currently employs 30,000 people and total exports in 2009 exceeded €6.5 billion. The diagnostic device sales in Europe were €10 billion in 2009, with Irish sales reaching an estimated €81 million.

Details of the 9 costs savings technologies researched by IMSTA are available from Justin Carty, IMSTA’s CEO (086 250 66 22)